Citigroup’s ESSA Pharma EPIX Stock Holding History

Citigroup’s Portfolio EPIX Stock Details EPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-599	Closed	-$2K	–	5959
2022 Q2	$2K	Sell	599 -759	-56%	-$4.24K	﹤0.01%	5878
2022 Q1	$8K	Buy	1,358 +411	+43%	+$3.61K	﹤0.01%	5632
2021 Q4	$13K	Buy	947 +161	+20%	+$1.79K	﹤0.01%	5508
2021 Q3	$6K	Sell	786 -7,030	-90%	-$112K	﹤0.01%	5567
2021 Q2	$223K	Buy	7,816 +7,396	+1,761%	+$215K	﹤0.01%	4188
2021 Q1	$12K	Buy	+420	New	+$9.76K	﹤0.01%	5528

Other funds holding EPIX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Citigroup's EPIX Position: Q3 2022 in Review

Citigroup sold out of ESSA Pharma (EPIX) in Q3 2022, closing a stake of 599 shares — an estimated $2K sold.

Citigroup first reported a position in EPIX in Q1 2021 and held it in 6 quarters. The position peaked at $223K in Q2 2021. 54 funds tracked by Wall St. Rank hold EPIX as of Q3 2022.

Citigroup reported no remaining ESSA Pharma position as of Q3 2022 after selling out during the quarter.
Citigroup sold 599 ESSA Pharma shares in Q3 2022, an estimated $2K.
Citigroup first reported a position in ESSA Pharma in Q1 2021 and held it in 6 quarters.
Citigroup's ESSA Pharma position peaked at $223K in Q2 2021.
54 funds tracked by Wall St. Rank held ESSA Pharma as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.